Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

The tumor promoting roles of HSP60 and HIF2α in gastric cancer cells

Authors: Wei-Wei Tong, Guang-Hui Tong, Hong Kong, Yong Liu

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

The roles of HSP60 and HIF2α in diagnosis, prognosis, and prevention and treatment of various human cancers have been detected. However, the combined roles of HSP60 and HIF2α on the prognosis of patients with gastric cancer remain unclear. In this work, we confirmed that the levels of HSP60 and HIF2α messenger RNA (mRNA) and protein were higher in gastric cancer tissues than that in matched normal tissues by using real-time PCR and Western blot. Furthermore, we confirmed that inhibition of HSP60 or HIF2α could induce apoptosis and inhibit cell mobility. Co-immunoprecipitation (co-IP) was performed to determine the interaction between HSP60 and HIF2α. Lastly, we confirmed that knockdown of HSP60 or HIF2α induced apoptosis in gastric cancer cells is negatively related to the MEK/ERK signaling in vitro. In summary, HSP60 or HIF2α protein expression may be a predictive marker for the prognosis of the patients with gastric cancer. Targeting HSP60 and HIF2α could be a future strategy to improve survival of gastric patients with poor prognosis.
Literature
1.
Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol. 2011;46:289–96.CrossRefPubMed
2.
Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem. 1997;378:609–16.PubMed
3.
Wang HX, Qin C, Han FY, Wang XH, Li N. HIF-2α as a prognostic marker for breast cancer progression and patient survival. Genet Mol Res. 2014;13:2817–26.CrossRefPubMed
4.
Tong WW, Tong GH, Chen XX, Zheng HC, Wang YZ. HIF2α is associated with poor prognosis and affects the expression levels of survivin and cyclin D1 in gastric carcinoma. Int J Oncol. 2015;46:233–42.PubMed
5.
Wu XH, Qian C, Yuan K. Correlations of hypoxia-inducible factor-1α/hypoxia-inducible factor-2α expression with angiogenesis factors expression and prognosis in non-small cell lung cancer. Chin Med J (Engl). 2011;124:11–8.
6.
Cohen M, Dromard M, Petignat P. Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecol Oncol. 2010;119:164–6.CrossRefPubMed
7.
Kaigorodova EV, Bogatyuk MV. Heat shock proteins as prognostic markers of cancer. Curr Cancer Drug Targets. 2014;14:713–26.CrossRefPubMed
8.
Soltys BJ, Gupta RS. Mitochondrial-matrix proteins at unexpected locations: are they exported? Trends Biochem Sci. 1999;24:174–7.CrossRefPubMed
9.
Faried A, Sohda M, Nakajima M, Miyazaki T, Kato H, Kuwano H. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer. 2004;40:2804–11.CrossRefPubMed
10.
Cappello F, Di Stefano A, D’Anna SE, Donner CF, Zummo G. Immunopositivity of heat shock protein 60 as a biomarker of bronchial carcinogenesis. Lancet Oncol. 2005;6:816.CrossRefPubMed
11.
Hamelin C, Cornut E, Poirier F, Pons S, Beaulieu C, Charrier JP, et al. Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. FEBS J. 2011;278:4845–59.CrossRefPubMedPubMedCentral
12.
Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007;98:201–13.CrossRefPubMed
13.
Li XS, Xu Q, Fu XY, Luo WS. Heat shock protein 60 overexpression is associated with the progression and prognosis in gastric cancer. PLoS One. 2014;9, e107507.CrossRefPubMedPubMedCentral
14.
Fu DZ, Cheng Y, He H, Liu HY, Liu YF. The fate of Krüppel-like factor 9-positive hepatic carcinoma cells may be determined by the programmed cell death protein 5. Int J Oncol. 2014;44:153–60.PubMed
15.
Sena JA, Wang L, Hu CJ. BRG1 and BRM chromatin-remodeling complexes regulate the hypoxia response by acting as coactivators for a subset of hypoxia-inducible transcription factor target genes. Mol Cell Biol. 2013;33:3849–63.CrossRefPubMedPubMedCentral
16.
Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA, Hankinson SE, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 2011;130:657–62.CrossRefPubMedPubMedCentral
17.
Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, Ekman P, et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS. 2008;116:888–95.CrossRefPubMed
18.
Xu X, Wang W, Shao W, Yin W, Chen H, Qiu Y, et al. Heat shock protein-60 expression was significantly correlated with the prognosis of lung adenocarcinoma. J Surg Oncol. 2011;104:598–603.CrossRefPubMed
19.
Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, et al. HSP60 predicts survival in advanced serous ovarian cancer. Int J Gynecol Cancer. 2013;23:448–55.CrossRefPubMed
20.
Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 1999;460:251–6.CrossRefPubMed
21.
Chen S, Duan G, Zhang R, Fan Q. Helicobacter pylori cytotoxin-associated gene A protein upregulates α-enolase expression via Src/MEK/ERK pathway: implication for progression of gastric cancer. Int J Oncol. 2014;45:764–70.PubMed
22.
Han XR, Sun Y, Bai XZ. The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells. Cell Signal. 2012;24:1713–21.CrossRefPubMed
23.
Lin Z, Zhang C, Zhang M, Xu D, Fang Y, Zhou Z, et al. Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer. PLoS One. 2014;9, e85296.CrossRefPubMedPubMedCentral
Metadata
Title
The tumor promoting roles of HSP60 and HIF2α in gastric cancer cells
Authors
Wei-Wei Tong
Guang-Hui Tong
Hong Kong
Yong Liu
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4783-2

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells

Original Article

The proliferation impairment induced by AQP3 deficiency is the result of glycerol uptake and metabolism inhibition in gastric cancer cells

Original Article

ECRG4 as a novel tumor suppressor gene inhibits colorectal cancer cell growth in vitro and in vivo

Original Article

PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma

Original Article

Relationship between five GWAS-identified single nucleotide polymorphisms and female breast cancer in the Chinese Han population

Original Article

Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits